Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis.
about
An antibody-recruiting small molecule that targets HIV gp120.Live attenuated mutants of Francisella tularensis protect rabbits against aerosol challenge with a virulent type A strain.Differential Cultivation of Francisella tularensis Induces Changes in the Immune Response to and Protective Efficacy of Whole Cell-Based Inactivated VaccinesDetoxified endotoxin vaccine (J5dLPS/OMP) protects mice against lethal respiratory challenge with Francisella tularensis SchuS4.Antibody targeting the ferritin-like protein controls Listeria infection.A broadly applicable approach to T cell epitope identification: application to improving tumor associated epitopes and identifying epitopes in complex pathogens.Fc receptor-targeting of immunogen as a strategy for enhanced antigen loading, vaccination, and protection using intranasally administered antigen-pulsed dendritic cellsDevelopment of functional and molecular correlates of vaccine-induced protection for a model intracellular pathogen, F. tularensis LVS.Tularemia vaccines: recent developments and remaining hurdles.A mucosal subunit vaccine protects against lethal respiratory infection with Francisella tularensis LVS.Identification of a live attenuated vaccine candidate for tularemia prophylaxisAntibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulationAntibodies contribute to effective vaccination against respiratory infection by type A Francisella tularensis strainsB cells regulate neutrophilia during Mycobacterium tuberculosis infection and BCG vaccination by modulating the interleukin-17 response.In vivo mechanisms involved in enhanced protection utilizing an Fc receptor-targeted mucosal vaccine platform in a bacterial vaccine and challenge model.The role of B cells and humoral immunity in Mycobacterium tuberculosis infectionA neonatal Fc receptor-targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection.Efficient mucosal vaccination mediated by the neonatal Fc receptor.Preclinical testing of a vaccine candidate against tularemia.Downmodulation of vaccine-induced immunity and protection against the intracellular bacterium Francisella tularensis by the inhibitory receptor FcγRIIB.Development of a Multivalent Subunit Vaccine against Tularemia Using Tobacco Mosaic Virus (TMV) Based Delivery System.Targeting of a Fixed Bacterial Immunogen to Fc Receptors Reverses the Anti-Inflammatory Properties of the Gram-Negative Bacterium, Francisella tularensis, during the Early Stages of InfectionMucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.Targeting a Neutralizing Epitope of HIV Envelope Gp120 by Immune Complex Vaccine.B cells and antibodies in the defense against Mycobacterium tuberculosis infectionTularemia vaccine development: paralysis or progress?Vaccination evokes gender-dependent protection against tularemia infection in C57BL/6Tac mice.An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.Increased susceptibility of IgA-deficient mice to pulmonary Francisella tularensis live vaccine strain infectionOral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A.Humoral and cell-mediated immunity to the intracellular pathogen Francisella tularensis.Differential requirements for protection against mucosal challenge with Francisella tularensis in the presence versus absence of cholera toxin B and inactivated F. tularensisEpitope-based vaccination against pneumonic tularemiaElicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120.Fc receptor-targeted mucosal vaccination as a novel strategy for the generation of enhanced immunity against mucosal and non-mucosal pathogens.Designing oral vaccines targeting intestinal dendritic cells.Chemically synthesized molecules with the targeting and effector functions of antibodies.Respiratory and oral vaccination improves protection conferred by the live vaccine strain against pneumonic tularemia in the rabbit model.Ex vivo antigen-pulsed PBMCs generate potent and long lasting immunity to infection when administered as a vaccine.
P2860
Q30381757-49E43C4B-6914-44CC-8FE4-4F2F757940DEQ30409782-F45982DF-13D7-4471-A608-4FE3BA173FAEQ30834372-3F5DE1A2-6CD8-4959-9060-671668FFB997Q33759497-FBDD2C89-DB3C-46B8-B136-1E7D0220F83FQ33963174-CABA6D8D-DFDB-41BA-9ADA-BAF59560CBE8Q34004266-2E9C8F1F-20C4-4590-B6C9-80BD861DA858Q34087802-B732737C-FAA0-4975-BE0F-F013D1BA9874Q34139968-784D5610-74AF-4885-A707-CE76DC936CF6Q34180914-63040000-92F0-46BA-904A-C1BDF07FEEA7Q34500312-79F4DBF0-98DE-4819-B65B-58AB70FFD8D6Q34684536-9675244A-BE11-4B67-820B-7AE9A204B6D5Q34694812-286A88F7-CC25-47D5-A364-AA9473190742Q34740339-FF2087C7-B56D-4073-B3B2-BDCFCE24F2D7Q34819635-0C7C977C-A38D-4D64-AF11-097E1D463EB1Q34890142-4975AF79-5521-4674-B700-1BAD11879575Q35039807-EB743DA8-D7E0-47E1-BBBC-B9FDF771A0FCQ35274924-7D4E90DD-AB8A-49DF-9D6B-ACA7D56950C4Q35399345-36EABC26-FC55-4D70-9A30-AE98C47CABDBQ35513176-9309D081-62D1-45EB-A0B4-7EC61AB3DFF5Q35563406-C429BD43-4923-4FEF-8AD5-6A6EDD2F02C2Q35670540-5546072C-B4E6-4140-9909-AFDA21690689Q35675388-8A1AEDEE-4148-40D6-933B-870C8E13B5E3Q35805480-8196CD5B-FF08-46A2-BE79-0840D3B7D898Q36157711-8BB08F9F-2112-49DD-90D3-8C38AC73A885Q36238031-9DD3A834-5A4C-4FF1-A5BA-0F4779457625Q36908692-AF1C4206-CFD2-437D-B864-3B4E2C73CCAFQ36999171-F05983B3-6EAB-49BD-97F1-8D8C6330D334Q37120769-8338FB91-DC80-4BE0-AAC2-1CF55715F021Q37123754-695869C8-4FA8-40CB-BAEF-9240CFF4E3A9Q37156774-CD060A09-1BFA-41B1-B0C5-5FF3E2D08608Q37287818-67F5451E-B2CE-4332-A016-553D5268CE9FQ37289261-D637664F-FBEC-4AD7-AAF9-EAE44DB83509Q37409665-A2961629-F98D-48EA-AE6B-1ADE1BE3A265Q37419234-5868B652-1241-4BAF-9146-EC8BCAA549E6Q37462829-5A3CDB14-2D54-452D-89AA-81BB756F5287Q37581435-9D780A17-E76A-4941-8CA5-E57D732F7EC8Q37849779-278B9FD0-5236-4886-B3FC-6642DAEFC935Q38928032-0F681386-BBC7-4406-94C0-2D7D96FE3434Q40093204-FD01208C-3AA9-46FF-8967-61BFE6775A4CQ40379071-2161C4E6-74C4-4D9B-8C80-51C25B01531B
P2860
Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Utilization of Fc receptors as ...... erium, Francisella tularensis.
@en
Utilization of Fc receptors as ...... erium, Francisella tularensis.
@nl
type
label
Utilization of Fc receptors as ...... erium, Francisella tularensis.
@en
Utilization of Fc receptors as ...... erium, Francisella tularensis.
@nl
prefLabel
Utilization of Fc receptors as ...... erium, Francisella tularensis.
@en
Utilization of Fc receptors as ...... erium, Francisella tularensis.
@nl
P2093
P2860
P1476
Utilization of Fc receptors as ...... erium, Francisella tularensis.
@en
P2093
Constantine Bitsaktsis
Deepak B Rawool
Dennis W Metzger
Diane R Gosselin
Edmund J Gosselin
Nitin V Kurkure
P2860
P304
P356
10.4049/JIMMUNOL.180.8.5548
P407
P577
2008-04-01T00:00:00Z